8-K: vTv Therapeutics' Type 1 Diabetes Program Placed on Clinical Hold by FDA

The FDA has placed a clinical hold on vTv Therapeutics' cadisegliatin program for type 1 diabetes due to an unresolved chromatographic signal found in a recent study.

Summary

• vTv Therapeutics has announced that the FDA has placed a clinical hold on its cadisegliatin program, including the CATT1 Phase 3 trial for type 1 diabetes.
• The hold was initiated due to the discovery of an unidentifiable chromatographic signal in a recent human ADME study.
• The FDA requires a single in vitro study to characterize this signal before the program can resume.
• No patients had been dosed in the CATT1 trial at the time of the hold.
• Past clinical studies of cadisegliatin, involving over 500 subjects, did not reveal any concerning safety issues.
• The company is working with the FDA to resolve the issue and resume enrollment as quickly as possible.

Sentiment

Score: 3

Explanation: The clinical hold is a significant negative development, impacting the company's timeline and potentially its valuation. While the company is working to resolve the issue, the uncertainty and delay warrant a low sentiment score.

Positives

• Cadisegliatin has demonstrated a favorable safety profile in over 500 subjects to date.
• The company is actively working with the FDA to resolve the clinical hold.
• Past clinical studies did not reveal any clinically concerning safety issues.
• Cadisegliatin has shown compelling efficacy and potential to improve glycemic control.

Negatives

• The FDA has placed a clinical hold on the cadisegliatin program, halting the CATT1 Phase 3 trial.
• An unidentifiable chromatographic signal was discovered in a recent ADME study, leading to the hold.
• The program cannot resume until the signal is characterized through an in vitro study.

Risks

• The clinical hold could delay the development and potential approval of cadisegliatin.
• The time and cost required to resolve the issue with the FDA are uncertain.
• There is a risk that the in vitro study may not resolve the issue, leading to further delays or program termination.
• The company's stock price may be negatively impacted by the clinical hold.

Future Outlook

The company anticipates working with the FDA to resolve the clinical hold and resume enrollment as quickly as possible, but the timing is uncertain.

Management Comments

• Patient safety is our top priority, and we appreciate the thoroughness of the FDA to better understand this signal, said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics.
• We are working diligently with the Agency to resolve the clinical hold and resume enrollment as quickly as possible.
• Cadisegliatin demonstrated compelling efficacy and a favorable safety profile in over 500 subjects dosed to date, and we are highly encouraged at the potential of cadisegliatin to improve glycemic control and be a much-needed oral therapy for type 1 diabetes.

Industry Context

The clinical hold highlights the regulatory challenges in drug development, particularly for novel therapies like glucokinase activators. It underscores the importance of thorough safety assessments and the potential for unexpected issues to arise during clinical trials.

Comparison to Industry Standards

• Clinical holds are not uncommon in the pharmaceutical industry, particularly during early-stage trials.
• Other companies developing novel diabetes treatments have also faced regulatory hurdles and delays.
• The need for additional in vitro studies to characterize unexpected signals is a standard practice in drug development.
• The impact of this hold will be compared to similar situations faced by companies like Novo Nordisk and Eli Lilly in their diabetes programs.

Stakeholder Impact

• Shareholders may experience a negative impact on the stock price due to the clinical hold.
• Patients with type 1 diabetes may experience a delay in the potential availability of a new treatment option.
• Employees of vTv Therapeutics may face uncertainty regarding the future of the cadisegliatin program.

Next Steps

• vTv Therapeutics will conduct a single in vitro study to characterize the chromatographic signal.
• The company will work with the FDA to resolve the clinical hold.
• The company will resume enrollment in the CATT1 trial once the clinical hold is lifted.

Key Dates

Keywords

clinical hold, cadisegliatin, type 1 diabetes, FDA, glucokinase activator, CATT1, ADME study, vTv Therapeutics, TTP399